Drugs Made In America Acquisition Corp. Units (DMAAU) - Net Assets
Based on the latest financial reports, Drugs Made In America Acquisition Corp. Units (DMAAU) has net assets worth $230.28 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($237.63 Million) and total liabilities ($7.36 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read total liabilities of Drugs Made In America Acquisition Corp. for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $230.28 Million |
| % of Total Assets | 96.9% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Drugs Made In America Acquisition Corp. Units - Net Assets Trend (2024–2024)
This chart illustrates how Drugs Made In America Acquisition Corp. Units's net assets have evolved over time, based on quarterly financial data. Also explore DMAAU asset base for the complete picture of this company's asset base.
Annual Net Assets for Drugs Made In America Acquisition Corp. Units (2024–2024)
The table below shows the annual net assets of Drugs Made In America Acquisition Corp. Units from 2024 to 2024. For live valuation and market cap data, see how much is Drugs Made In America Acquisition Corp. worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-244.85 | -- |
Equity Component Analysis
This analysis shows how different components contribute to Drugs Made In America Acquisition Corp. Units's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $986.00 | % |
| Total Equity | $-244.00 | 100.00% |
Drugs Made In America Acquisition Corp. Units Competitors by Market Cap
The table below lists competitors of Drugs Made In America Acquisition Corp. Units ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Timberland Bancorp Inc
NASDAQ:TSBK
|
$307.88 Million |
|
Hansae Co
KO:105630
|
$307.99 Million |
|
NCT Alliance Bhd
KLSE:0056
|
$308.04 Million |
|
Changzhou Tiansheng New Materials Co Ltd
SHE:300169
|
$308.15 Million |
|
Oneconnect Financial Technology Co
NYSE:OCFT
|
$307.70 Million |
|
3I Group PLC
LSE:III
|
$307.70 Million |
|
Crowell Development Corp
TW:2528
|
$307.67 Million |
|
TA-I Technology Co Ltd
TW:2478
|
$307.58 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Drugs Made In America Acquisition Corp. Units's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares Drugs Made In America Acquisition Corp. Units's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2024-12-31 | $0.00 | $10.58 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Drugs Made In America Acquisition Corp. Units utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-454.60 |
Industry Comparison
This section compares Drugs Made In America Acquisition Corp. Units's net assets metrics with peer companies in the Shell Companies industry.
Industry Context
- Industry: Shell Companies
- Average net assets among peers: $224,857,490
- Average return on equity (ROE) among peers: 3.02%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Drugs Made In America Acquisition Corp. Units (DMAAU) | $230.28 Million | 0.00% | 0.03x | $307.76 Million |
| Artius II Acquisition Inc. Class A Ordinary Shares (AACB) | $-60.27K | 0.00% | 0.00x | $230.18 Million |
| Artius II Acquisition Inc. Units (AACBU) | $-60.27K | 0.00% | 0.00x | $265.09 Million |
| Ares Acquisition Corporation II (AACT) | $11.15K | -0.14% | 45.93x | $587.05 Million |
| AA Mission Acquisition Corp. (AAM) | $1.54 Billion | 21.89% | 4.12x | $409.92K |
| Altenergy Acquisition Corp (AEAE) | $214.04 Million | 5.44% | 0.10x | $72.25 Million |
| Activate Energy Acquisition Corp. Class A Ordinary Share (AEAQ) | $223.53 Million | 0.00% | 0.04x | $235.74 Million |
| Aimei Health Technology Co., Ltd Ordinary Share (AFJK) | $69.76 Million | 0.25% | 0.01x | $163.82 Million |
| Aifeex Nexus Acquisition Corporation (AIFE) | $86.16 Million | -0.10% | 0.01x | $91.13 Million |
| AI TRANSPORTATION ACQUISITION CORP Ordinary shares (AITR) | $-4.24K | 0.00% | 0.00x | $86.22 Million |
| Alchemy Investments Acquisition Corp 1 Class A Ordinary Shares (ALCY) | $115.20 Million | 2.86% | 0.05x | $49.57 Million |
About Drugs Made In America Acquisition Corp. Units
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in Fort Lauderdale, Florida.